AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05158348
Drug: Dexmedetomidine Hydrochloride
RxNorm normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group A will receive post-operative nebulised dexametomidine and lidocaine.
Trial: NCT05158348
Drug: Nebulized lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group B will receive post-operative will receive nebulised lidocaine
Trial: NCT05158348
Drug: Local infiltration of lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: group C will receive intra-operative local infiltration of lidocaine
Trial: NCT04802746
Drug: Alprazolam
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study participants will receive Staccato alprazolam Dose 1 and Staccato alprazolam Dose 2 at pre-specified time points in Part A. Study participants will receive single dose of Staccato alprazolam at pre-specified time points in Part B.
Trial: NCT05771428
Drug: ABBV-552
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT06004661
Drug: 68Ga-PSMA-11
RxNorm normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of approximately 150 MBq
Trial: NCT04914897
Drug: THOR-707
RxNorm normalized name: IL-2 variant THOR-707
DrugBank: Pegenzileukin (DB17495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion: solution for infusion
Trial: NCT04914897
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infusion: solution for infusion
Trial: NCT05091346
Drug: E7386
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: E7386 tablet.
Trial: NCT05091346
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab IV infusion.
Trial: NCT05091346
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib capsule.
Trial: NCT04714372
Drug: Daratumumab/rHuPH20
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab 1800 mg co-formulated with 30,000 units of hyaluronidase (rHuPH20) given subcutaneously into subcutaneous tissue of the abdomen approximately 3 inches \[7.5 cm\] to the right or left of the navel over approximately 3-5 minutes on Day -12 and Day -5 prior to the 1st FT538 infusion, and on Day +3, Day+10, and Day+17 approximately 48 hours after each FT538 infusion.
Trial: NCT04714372
Drug: FT538
RxNorm normalized name: Fidanacogene elaparvovec
DrugBank: Fidanacogene elaparvovec (DB16783)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FT538 is administered as an IV infusion via gravity using an IV administration set with an in-line filter at the patient's assigned dose levels (DL) on Day 1, Day 8, and Day 15
Trial: NCT04714372
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 25 mg/m\^2 is administered as a 1 hour intravenous (IV) infusion per institutional guidelines once a day on 2 consecutive days (Day -4, and Day -3).
Trial: NCT00189761
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06098014
Drug: Thalidomide Capsules
RxNorm normalized name: Thalidomide Capsules
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To see safety and efficacy of Thalidomide in Transfusion depended thalassemia
Trial: NCT05041101
Drug: Eribulin Mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT05041101
Drug: Grapiprant
RxNorm normalized name: Grapiprant
DrugBank: Grapiprant (DB12836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00000851
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000851
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002103
Drug: Trimetrexate glucuronate
RxNorm normalized name: Trimetrexate Glucuronate
DrugBank: Trimetrexate (DB01157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06362408
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Older patients who have used dexmedetomidine(safe use range: 0.2\~1.0 μg/(kg·h)) for anesthesia induction or maintenance during surgery were classified as the DEX group. On the contrary, patients who did not use dexmedetomidine throughout the entire anesthesia process were identified as the Non-DEX group.
Trial: NCT06203431
Drug: ET-26
RxNorm normalized name: Chloride/Dextrose/Potassium/Sodium 290 MG/1 PACKET-6 GM/1 PACKET-180 MG/1 PACKET-260 MG/1 PACKET Oral Powder for Solution
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: freeze-dried powder injection，The initial dose is 0.8 mg/kg, with an additional 50% starting dose if needed. single dose, Infusion time was 60s ± 5s.
Trial: NCT06203431
Drug: Etomidate Injectable Emulsion
RxNorm normalized name: etomidate Injection
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lipid emulsion ，The initial dose is 0.3 mg/kg, with an additional 50% starting dose if needed.single dose, Infusion time was 60s ± 5s.
Trial: NCT06487949
Drug: valsartan-amlodipine 80/5 mg FDC
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: fix dose combination of valsartan 80 mg and Amlodipine 5 mg given as single pill
Trial: NCT06487949
Drug: valsartan 80 mg and amlodipine 5 mg as free combination
RxNorm normalized name: valsartan and amlodipine
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Free combination of valsartan 80 mg and amlodipine 5 mg given separately
Trial: NCT04722718
Drug: Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sintilimab:200mg,ivgtt,d1,21days/cycle;Apatinib:250mg po,d1-14days,21days/cycle;Albumin-Bound Paclitaxel(Nab-Paclitaxel):125mg/m2,ivgtt,d1,d8,21days/cycle;Carboplatin:AUC=1.5,ivgtt,d1,d8, 21days/cycle.Monitoring of blood routine, biochemical and urine routine, electrocardiogram, and record the patient's drug-related adverse reactions every cycle,according to the curative effect of patients, compliance and tolerance, neoadjuvant therapy 6 cycles,every 2 cycles to evaluate curative effect (ultrasonic, breast X-ray CT, bone scan, brain, lungs, assessment and breast MRI imaging).
Trial: NCT00226642
Drug: Sertralin
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05434546
Drug: Sepranolone
RxNorm normalized name: Sepranolone
DrugBank: Sepranolone (DB12972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with 10 mg Sepranolone s.c. twice weekly for 12 weeks alongside patient's standard of care Tourette treatment.
Trial: NCT04960891
Drug: Tebentafusp
RxNorm normalized name: Tebentafusp
DrugBank: Tebentafusp (DB15283)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Concentrate solution for intravenous infusion
Trial: NCT05742620
Drug: anlotinib+CAPEOX/SOX
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with colorectal cancer use the anlotinib+CAPEOX protocol, and patients with gastric cancer use the anlotinib+SOX protocol.~Anlotinib: 12mg, administered once a day on day 1-14, taken about half an hour before breakfast (the time of daily administration should be the same as much as possible), delivered with warm water, repeated once every three weeks;~CAPEOX: capecitabine 1000mg/m2 each time, oral, twice a day, 1-14 days; Oxaliplatin: 130mg/m2 iv drip d1.~SOX: Tegio: 100mg/day, continuous medication for 2 weeks, stop for 1 week; Oxaliplatin: 130mg/m2 iv drip d1.
Trial: NCT04516681
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg/Kg intravenously every 3 weeks
Trial: NCT00000899
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000899
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00000899
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00000899
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00173667
Drug: Nifedipine 30 mg GITS
RxNorm normalized name: nifedipine 30 MG
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05615467
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered orally.
Trial: NCT05615467
Drug: Iohexol
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT05578404
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vit D is a fat-soluble vitamin, provided by sunlight and activated by kidneys and liver.
Trial: NCT01320410
Drug: ISM®
RxNorm normalized name: Isosmotic Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05558410
Drug: VX-548
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration.
Trial: NCT04779645
Drug: REMD-477
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 12-Week, once weekly subcutaneous injection with 70mg REMD-477
Trial: NCT05139030
Drug: bupivacaine liposome injectable suspension
RxNorm normalized name: bupivacaine liposome Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adductor canal block with EXPAREL
Trial: NCT05139030
Drug: Bupivacaine Hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adductor Canal Block with bupivacaine HCl
Trial: NCT05159193
Drug: trastuzumab (H)
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1, q3w
Trial: NCT05159193
Drug: pertuzumab (P)
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1, q3w
Trial: NCT05159193
Drug: docetaxel (T)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel (T) 90\~100 mg/m\^2, i.v., d1, q3w
Trial: NCT05159193
Drug: docetaxel (T)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel (T) 75 mg/m\^2, i.v., d1, q3w
Trial: NCT05159193
Drug: carboplatin (Cb)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: carboplatin (Cb) AUC 6, i.v., d1, q3w
Trial: NCT05809453
Drug: Cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine will be administered intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
Trial: NCT04558502
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic for H. pylori eradication
Trial: NCT05809453
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine will be administered intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
Trial: NCT04558502
Drug: colloidal bismuth pectin
RxNorm normalized name: bismuth / pectin
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric mucosal protective drug with anti-H. pylori effect
Trial: NCT04558502
Drug: esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor
Trial: NCT01089192
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05647993
Drug: Cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All the participants will receive the cefazolin intravenously. The dosage of the cefazolin is depend on participant's weight. The participant with weight less than 80kg will receive cefazolin 1 gm and between 80-120kg will receive cefazolin 2 gm and for the participant with more than 120kg will receive cefazolin 3 gm before the incision.
Trial: NCT05647993
Drug: Sodium Chloride 0.9% Intravenous Solution
RxNorm normalized name: Sodium Chloride 0.9% Intravenous Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For the placebo group will receive the cefazolin intravenously and 0.9% NaCl 100ml before the incision
Trial: NCT06107829
Drug: Valbenazine Oral Capsule
RxNorm normalized name: valbenazine Oral Capsule
DrugBank: Valbenazine (DB11915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-label twenty-four-week treatment with valbenazine oral capsules (up to 80 mg/day) to test the safety and effectiveness of this medication in ameliorating the signs of tardive dyskinesia in persons with intellectual disability.
Trial: NCT04691661
Drug: Radotinib HCl 50 mg
RxNorm normalized name: meclizine hydrochloride 50 MG
DrugBank: Radotinib (DB12323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled subject will continue to administer Radotinib 50mg/day, 100mg/day, 150mg/day, 200mg/day, depending on the dose level once daily for 6 months.
Trial: NCT06435507
Drug: IM-250 (50 mg)
RxNorm normalized name: triclabendazole 250 MG
DrugBank: Triclabendazole (DB12245)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT06435507
Drug: IM-250 (100 mg)
RxNorm normalized name: triclabendazole 250 MG
DrugBank: Triclabendazole (DB12245)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT06435507
Drug: IM-250 (200 mg)
RxNorm normalized name: triclabendazole 250 MG
DrugBank: Triclabendazole (DB12245)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT06435507
Drug: IM-250 (400 mg)
RxNorm normalized name: triclabendazole 250 MG
DrugBank: Triclabendazole (DB12245)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT03528681
Drug: Sodium Zirconium Cyclosilicate 5g
RxNorm normalized name: SODIUM ZIRCONIUM CYCLOSILICATE 5GM/PKT
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Suspension administered Sodium Zirconium Cyclosilicate 5g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
Trial: NCT03528681
Drug: Sodium Zirconium Cyclosilicate 10g
RxNorm normalized name: SODIUM ZIRCONIUM CYCLOSILICATE 10GM/PKT
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Suspension administered Sodium Zirconium Cyclosilicate 10g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
Trial: NCT04886765
Drug: ALMB-0168
RxNorm normalized name: ALMB-0168
DrugBank: ALMB-0168 (DB16926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
Trial: NCT01374282
Drug: Cuprimine (penicillamine)
RxNorm normalized name: penicillamine Oral Capsule [Cuprimine]
DrugBank: Penicillamine (DB00859)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage determined by the physician based on indication for treatment
Trial: NCT02762591
Drug: Pimavanserin tartrate
RxNorm normalized name: Pimavanserin tartrate
DrugBank: Pimavanserin (DB05316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimavanserin tartrate 40 mg, tablet, taken as two 20 mg tablets, once daily by mouth
Trial: NCT05645094
Drug: Envafolimab
RxNorm normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive single drug therapy of Envafolimab (300mg) once every two weeks. Patients who do not have tumor regression after 3 months of treatment should be judged by the investigator whether to adopt standard chemoradiotherapy plus surgery. Patients with tumor regression should continue to receive Envafolimab therapy until 6 months. For patients who do not reach complete clinical response (cCR) after 6 months of treatment, the investigator shall determine whether to perform standard chemoradiotherapy or radical surgery. For patients who reach cCR, they could receive the observation waiting or local resection which depend on the investigator. Patients should be followed up until reaching cCR or 3 years after surgery.
Trial: NCT05325164
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methadone
Trial: NCT05325164
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine
Trial: NCT06417684
Drug: Amitriptyline
RxNorm normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg prescribed to be taken once daily for 90 days each evening.
Trial: NCT05200988
Drug: Ipilimumab + nivolumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction with immune checkpoint blockade: ipilimumab 3mg/kg on day 1, pilimumab 3mg/kg plus nivolumab 1mg/kg on day 22, and nivolumab 3mg/kg on day 43~Response evaluation after the last cycle of checkpoint inhibition.~Chemoradiation will start 10-12 weeks after start of checkpoint inhibition according to the following scheme:~* Mitoycine C (12mg/m2) on the first day of radiotherapy, followed by either 5-fluorouracil intravenously (500mg/m2) five days a week during week one and four of radiation, or oral capecitabin (2x825mg/m2) every day during the radiation period~* Radiation with a preference for a four-week schedule, in which 55 Gy will be administered using intensity modulated radiation therapy
Trial: NCT04887298
Drug: Liposomal Annamycin (L-Annamycin)
RxNorm normalized name: Ansamycin
DrugBank: Annamycin (DB06420)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hour intravenous (IV) infusion of L-Annamycin on Day 1 followed by 20 days off of study drug (i.e., 1 treatment cycle= 21 days)
Trial: NCT00071708
Drug: Duloxetine Hydrochloride
RxNorm normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06598943
Drug: Eltrekibart
RxNorm normalized name: Eltrekibart
DrugBank: Eltrekibart (DB19017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered
Trial: NCT06598943
Drug: Mirikizumab
RxNorm normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered
Trial: NCT04243824
Drug: Gallium 68 Macro-aggregated albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Gallium nitrate (DB05260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The radiotracer, Ga-68 MAA, will be administered prior to PET/MRI scan.
Trial: NCT05809687
Drug: DKP21102_C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04996719
Drug: Rapamune
RxNorm normalized name: Rapamune
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: We will start the dose at 0.5mg capsule every other day for 2 weeks. If participants tolerate this dose and trough blood levels are (≤4ng/mL), the dose of rapamycin will be increased to 0.5mg daily for the duration of the study. If necessary, dose can remain at 0.5 mg every other day, depending on the trough level. To avoid immunosuppression, we will target lower dose of rapamycin, maintain lower trough serum levels (≤4ng/mL).
Trial: NCT04711837
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol for induction of general anesthesia.
Trial: NCT05257122
Drug: Fruquintinib
RxNorm normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib 5mg qd, d1-21, q28d
Trial: NCT04937699
Drug: Standard-DAPT of Ticagrelor plus aspirin
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects continue for another 11 months
Trial: NCT04937699
Drug: Sequential monotherapy of Ticagrelor and clopidogrel
RxNorm normalized name: Ticagrelor
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects switch to ticagrelor 90mg bid for 5 months; then clopidogrel 75mg qd, for another 6 months.
Trial: NCT05071339
Drug: Ganirelix Acetate, Cetrolix Acetate
DrugBank: Ganirelix (DB06785)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-6 days of 0.25mg GnRH antagonist starting day 2-3 of the menstrual cycle prior to the administration of the original protocol.